Heat Biologics Inc (HTBX) was Initiated by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Jun 20, 2016.
Heat Biologics Inc closed down -0.01 points or -1.65% at $0.595 with 1,29,660 shares getting traded on Friday. Post opening the session at $0.6, the shares hit an intraday low of $0.58 and an intraday high of $0.61 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Mar 23, 2016, Michael Kharitonov (director) purchased 900,000 shares at $0.75 per share price.
Heat Biologics Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live genetically-modified irradiated human cells which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens thus harnessing a patient’s own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.